Dr.  

Mark Lebwohl

, United States


Presentations

PSO-LONG: use of the psoriasis symptom inventory in a Phase 3 trial studying the long-term efficacy and safety of fixed-dose combination calcipotriol 0.005% and betamethasone diproprionate 0.064% foam in patients with psoriasis 09 October 2019 00:00 - 00:00
Understanding the Burden of Moderate Psoriasis: The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey 09 October 2019 00:00 - 00:00
Relationship of Serum Glucose to Efficacy and Safety of Tildrakizumab Treatment for Psoriasis in Patients with and without Metabolic Syndrome from reSURFACE 1 and reSURFACE 2 09 October 2019 00:00 - 00:00
Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 reSURFACE 1 Study 09 October 2019 00:00 - 00:00
Efficacy and safety of calcipotriol plus betamethasone dipropionate cutaneous foam in treating scalp psoriasis: a review of data from two phase 2 studies 09 October 2019 00:00 - 00:00

Abstracts

PSO-LONG: use of the psoriasis symptom inventory in a Phase 3 trial studying the long-term efficacy and safety of fixed-dose combination calcipotriol 0.005% and betamethasone diproprionate 0.064% foam in patients with psoriasis Psoriasis More
Efficacy and safety of calcipotriol plus betamethasone dipropionate cutaneous foam in treating scalp psoriasis: a review of data from two phase 2 studies Psoriasis More